Full video transcriptClick to expand
Auto-generated transcript of @drafroese's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00What I'm about to share with you should change how you think about dementia forever.
- 0:04For a long time now, the medical community has thought of dementia and Alzheimer's disease as
- 0:09tau proteins and amyloid plaques. Like they've been the whole story. And we've focused on treating
- 0:15these plaques and tingles. But unfortunately, the treatments we have, they're just not good.
- 0:21But here's the thing, dementia, not just Alzheimer's dementia, is neurodegeneration.
- 0:27It's neurons literally failing to operate. And that failure starts years before plaques and
- 0:33tangles ever show up. So okay, what drives the failure of neurons? It's this chronic inflammation,
- 0:40metabolic dysfunction, mitochondrial breakdown, and insulin resistance. See, it's not just a brain
- 0:46problem. It's a whole body metabolic breakdown that shows up in the brain last. So if dementia
- 0:52starts with inflammation in the body and brain, you'd think our treatments would treat those things.
- 0:58But they're not, not even close. And to be completely honest with you, and this is just my
- 1:02experience, not that of all doctors. But if you've ever had a job selling something that you couldn't
- 1:08get behind, you just felt like you were having to fake it in order to sell the product. That's
- 1:14kind of how I felt prescribing these drugs. I just haven't seen them make real change. And it's
- 1:21hard for me to convince people that they're worth taking. Now, please don't stop taking any
- 1:25medication or convince somebody else that they should stop taking a medication because you're watching
- 1:29this video. I am just a doctor on YouTube. I am not your doctor. And none of this is meant to be
- 1:35medical advice for me to you. Alright, so let's get rid of the negative talk here and focus on
- 1:39some more positive things because I've come across a lot. I'm going to share with you some
- 1:43research that is very promising. And also some of my top suggestions of supplements that in theory
- 1:49can give you a fighting chance of avoiding dementia. Basically, we're just going to go
- 1:53upstream from the brain problem. Okay, have you heard of Alzheimer's disease being called type
- 1:57three diabetes? Interesting, right? Well, here's why they say that. So research is actually showing
- 2:03that just like how the body becomes insulin resistant and type two diabetes, the brain is
- 2:10actually becoming insulin resistant as well. Insulin resistance in a grand scheme of things is
- 2:16where the messaging of insulin where you're supposed to be able to take sugar from point A
- 2:21to point B inside the cells, the messaging of that gets all gummed up and it just doesn't work right.
- 2:28So sugar doesn't go from point A to point B. Imagine having like a big old traffic jam in your
- 2:34brain's metabolism and things just aren't working right. I don't know if that was I tried. But that's
- 2:39what I'm talking about. See with insulin resistance, the brain can feel like it's starving for sugar
- 2:45when it's swimming in a sea of blood sugar. It just can't use it because the messaging to get it to
- 2:52use it is not working right. And it's been shown that that chronic starvation leads to more amyloid
- 2:58plaques, more tau proteins, weaker synapses, chronic inflammation and faster cognitive decline.
- 3:05So dementia isn't just plaques and tangles. It's metabolic failure in the brain. So now you can
- 3:11see why diabetes, chronic inflammation and insulin resistance increase dementia risk years before it
- 3:16ever shows up. And in my opinion, our treatments should be aimed at fighting those problems. In fact,
- 3:23this is why the GLP drugs, semaglutide, turds up a tide, red a true tide are literally being
- 3:29studied for dementia right now because they have the power to fix inflammation and insulin resistance.
- 3:34You know, everybody's been terrified of overusing the GLP drugs, but in my opinion, and I might
- 3:39regret saying this in 10 years, but I've seen them do more good than harm. The GLP drugs are just
- 3:44one type of peptide therapy showing huge promise in the world of dementia. And this is a perfect
- 3:50opportunity to talk about other peptides that work even more directly on the brain's ability
- 3:56to repair itself. This is where it gets really interesting. There's a peptide called dihexa.
- 4:01It's known for its ability to increase neuroplasticity. And here's the research on dihexa.
- 4:06The dihexa has been shown to cross the blood brain barrier and it activates the strongest
- 4:12neuroplasticity pathway we have, the HGF C-Met or hepatocyte growth factor to C-Met receptor
- 4:20pathway. In animal studies, dihexa has been shown to be up to a million times more potent than BDNF
- 4:28or brain derived neurotrophic factor, which is basically the brain's master switch for neuroplasticity.
- 4:35This means that dihexa has the ability to drive synaptic growth at levels we've never seen from
- 4:42a natural molecule. Dihexa has been shown to reverse cognitive deficits in Alzheimer's models
- 4:49and motor deficits in Parkinson's models. Now, these are animal studies. They're not human studies.
- 4:54And I have to say that there's some hesitancy in researching dihexa on humans. And that's because
- 5:00the HGF C-Met pathway is also very heavily involved in cancer growth. So there's a huge
- 5:08theoretical risk of using it and promoting tumor growth. So dihexa kind of sits in this place of
- 5:14potentially revolutionary and potentially dangerous. We just don't know. Now, if you're like me,
- 5:20risk versus benefit might pop into question here and you might ask yourself as a question,
- 5:25okay, what's worse having cancer or losing your mind? And I'm not going to answer that here.
- 5:30It's just a personal opinion and feel free to start a war about it in the comments. Just giving
- 5:35us on the chew on. Now, dihexa was potentially the most potent neuroplasticity peptide that I
- 5:40could come up with. But let me give you a quicker rundown of some serious contenders. This is SS-31.
- 5:46It's a mitochondrial membrane stabilizer. It's a peptide that travels into the inner mitochondrial
- 5:53membrane where all of your ATP production happens and it stabilizes that membrane from getting
- 5:59unfolded, which it tends to do with inflammation and oxidative stress. And so it helps preserve
- 6:05ATP production, brain derived neurotrophic factor signaling, and it protects synapses from breaking
- 6:11down. That's what's been shown in the research. It literally has been shown to improve memory and
- 6:16inflammation in animal studies. Honestly, it's one of the most promising mitochondrial therapies
- 6:20that we've seen. And the FDA has approved it for human use even just not for this purpose.
- 6:27Another one is humanin. Humanin is a peptide that your mitochondria make and its entire job is
- 6:33to protect cells from dying and get this. It was first discovered in the brain of an Alzheimer's
- 6:38patient. It was found to be the thing keeping neurons alive when everything else around them
- 6:44was starting to fail. In a nutshell, research shows that humanin blocks cell death pathways
- 6:50defends neurons from amyloid beta damage, reduces mitochondrial damage by reducing
- 6:56oxidative damage, improves insulin sensitivity, and improves cognitive function and memory in mice
- 7:03with Alzheimer's disease. Mott C, this is another mitochondrial peptide that you make, and its job
- 7:10is completely different from humanin. If humanin is preventing cells from dying, Mott C basically
- 7:16helps keep the entire system functioning in the first place. Now, here's the wild part. Mott C
- 7:21is basically an exercise mimetic. It turns on the things that also get turned on when you exercise
- 7:28all the good things like mitochondrial biogenesis, fatty acid, oxidation, and considering how protective
- 7:35exercise is for the brain, well, you understand how this could be a big deal. In relation to dementia,
- 7:42here's what the research shows on Mott C. It improves mitochondrial quality control,
- 7:47meaning your neurons can repair their power systems instead of letting them fail. It activates key
- 7:54metabolic pathways that reduce inflammation in the brain, actually strengthens the blood brain
- 7:59barrier, which is huge because barrier breakdown is actually something that we see in dementia,
- 8:05and it reduces neural inflammatory conditions in stress responses. In animal studies,
- 8:11Mott C has been shown to improve cognitive function and memory. Now, we aren't prescribing these things.
- 8:16They're in a very gray area in research and medicine, but the science is fascinating. Okay,
- 8:22so those were my favorite things to talk about, but I can't ignore supplements. Keep in mind,
- 8:26supplements are not substitutes for good sleep, exercise, and nutrition. Oh, and somebody told me
- 8:31that I should probably mention on a video that I have a degree in nutrition science. A lot of biochem
- 8:36as it applies to the body, actually. But anyway, if I were worried about my brain,
- 8:40here's what I would consider supplementing with NAD, or it's precursors, the NMN or NR.
- 8:47I've actually said this many times in videos, but NAD is like a battery charger to your
- 8:51mitochondria. You need it to make energy and levels of it fall as we get older. You see, over time,
- 8:57as we age, we have less NAD and stress and inflammation actually use more of it than we tend to replace
- 9:04it. Research has literally shown that very low levels of NAD correlate with Alzheimer's dementia.
- 9:10And I feel like that's all you need to know. Omega threes. If you want a no-brainer brain
- 9:14supplement, take omega threes, especially ones with high DHA. DHA is brain building material,
- 9:21packed in your neurons and synapses. High DHA intake is associated with lower risk for dementia.
- 9:28I would look for a supplement that's got 1000 milligrams of DHA and EPA with DHA being
- 9:34prioritized. CoQ10. CoQ10 is essential for energy production and mitochondrial function.
- 9:41It also acts as an antioxidant in cells. Levels also tend to drop with age, and they really drop
- 9:48with statin use. And so if you have an older person on a statin and you're worried about their memory,
- 9:53put them on CoQ10. Magnesium 3 and 8. Most people are actually low in magnesium and 3 and 8 is the
- 10:00version that can cross the blood brain barrier. It is thought to support synaptic plasticity and
- 10:05memory. Fun fact, I have nightmares when I take this supplement, so I tend to stay away from it.
- 10:10Let me know if you do too. Curcumin. This is a potent anti-inflammatory and antioxidant with
- 10:16multiple brain-relevant pathways. Now, regular curcumin actually absorbs terribly. So you have to get a
- 10:22highly bioavailable type. Alpha lipoic acid or ALA. ALA is also an antioxidant, but it's also an
- 10:29antioxidant recycler. It's kind of like a cleanup crew inside your neurons. You can think of ALA as
- 10:34something that reduces oxidative stress, supports energy production, and supports other antioxidant
- 10:40functioning. It's actually one of the few supplements that's been shown to have a possible
- 10:45cognitive decline slowing effect. Lion's Mane. Lion's Mane is something that people swear by for
- 10:50nerve growth. It contains compounds that may boost something called nerve growth factor. It's
- 10:56basically the brain's please grow new neurons signal. Early studies on this are showing mild
- 11:02cognitive improvement. Just know that this is not a treatment. It's just a supplement. And here's
- 11:07something that we don't talk about enough. B vitamins. B12 deficiency can show up as cognitive
- 11:13impairment. And so it's important to get your B12 levels checked if you're having memory issues.
- 11:17You can also check levels of homocysteine in your blood. High homocysteine is a huge risk factor
- 11:22for brain function decline. And B vitamins can help bring that down. Vitamin D. If I ran labs on 100
- 11:29people with brain fog or cognition issues, many of them would have a vitamin D deficiency. People
- 11:34with low vitamin D show lower mood, poor cognitive function, fatigue, worse executive function,
- 11:41and higher risk of developing dementia. These are showing up as correlations time and time again.
- 11:48Okay. So I hope that showed you that dementia is not just a disease in the brain itself. It's
- 11:54stemming from inflammation. A whole body problem that just manifests lastly up here. But these new
- 12:00strategies coming out of the woodworks are something that I'm getting on board with. You know, fixed
- 12:04metabolism, fixed inflammation, fix the mitochondria and support neuroplasticity. We're stepping
- 12:10outside the box because staying inside of it has just not worked. I'm Dr. Ashley Phrazy. I run a
- 12:15direct primary care clinic in Mesa, Arizona. It's just where my patients pay me directly instead
- 12:20of using insurance. And I like it better that way. If you like this video, please hit like for me.
Peptides for dementia prevention: hype check on TikTok's latest brain claims
Quick answer
The video argues that dementia is primarily a metabolic disorder driven by brain insulin resistance, chronic inflammation, and mitochondrial dysfunction, and that peptides including GLP-1 receptor agonists and the experimental compound dihexa offer more upstream intervention than current FDA-approved Alzheimer's drugs. Dihexa activates the HGF/c-Met receptor pathway and showed dramatic pro-cognitive effects in rodent models, but human trials have not been conducted, partly due to concerns about the oncogenic potential of systemic HGF/c-Met upregulation. GLP-1 agents are being studied in active human trials for cognitive outcomes, but no results yet support prescribing them specifically for dementia prevention or treatment.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Peptides for dementia prevention: hype check on TikTok's latest brain claims, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Peptides for dementia prevention: hype check on TikTok's latest brain claims should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Peptides for dementia prevention: hype check on TikTok's latest brain claims" from Dr. Ashley Froese. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The video argues that dementia is primarily a metabolic disorder driven by brain insulin resistance, chronic inflammation, and mitochondrial dysfunction, and that peptides including GLP-1 receptor agonists and the experimental compound dihexa offer more upstream intervention than current FDA-approved Alzheimer's drugs.
The reason this review is not generic is the source wording and the canonical claim label "peptides doctor reveals top peptides supplements to help you avoid de." In this clip, the useful excerpt is: "What I'm about to share with you should change how you think about dementia forever." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The video argues that dementia is primarily a metabolic disorder driven by brain insulin resistance, chronic inflammation, and mitochondrial dysfunction, and that peptides including GLP-1 receptor agonists and the experimental compound dihexa offer more upstream intervention than current FDA-approved Alzheimer's drugs.
FormBlends verdict
Peptide social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The video argues that dementia is primarily a metabolic disorder driven by brain insulin resistance, chronic inflammation, and mitochondrial dysfunction, and that peptides including GLP-1 receptor agonists and the experimental compound dihexa offer more upstream intervention than current FDA-approved Alzheimer's drugs. Dihexa activates the HGF/c-Met receptor pathway and showed dramatic pro-cognitive effects in rodent models, but human trials have not been conducted, partly due to concerns about the oncogenic potential of systemic HGF/c-Met upregulation. GLP-1 agents are being studied in active human trials for cognitive outcomes, but no results yet support prescribing them specifically for dementia prevention or treatment.
- The 2020 Lancet Commission (Livingston et al.) identified 12 modifiable risk factors covering roughly 40% of dementia cases, with midlife cardiovascular and metabolic health among the strongest targets.
- The 'type 3 diabetes' label for Alzheimer's comes from De la Monte and Wands (2008) and reflects genuine impairment of brain insulin signaling, but it remains a research hypothesis, not a clinical classification.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- The 2020 Lancet Commission (Livingston et al.) identified 12 modifiable risk factors covering roughly 40% of dementia cases, with midlife cardiovascular and metabolic health among the strongest targets.
- The 'type 3 diabetes' label for Alzheimer's comes from De la Monte and Wands (2008) and reflects genuine impairment of brain insulin signaling, but it remains a research hypothesis, not a clinical classification.
- Dihexa has shown dramatic pro-cognitive effects in rodent models (McCoy et al., 2013) but has never been tested in humans, and its mechanism involves the HGF/c-Met pathway, which is also implicated in tumor growth.
- GLP-1 receptor agonists including semaglutide are in active human trials for cognitive outcomes, but no published trial to date supports prescribing them specifically to prevent or treat dementia.
- Lecanemab (van Dyck et al., 2023, NEJM) demonstrated that clearing amyloid plaques slows decline by only 27% versus placebo, lending credibility to the argument that amyloid alone is not the full story.
- Dihexa is sold through unregulated peptide suppliers with no standardized dosing, no human safety profile, and no FDA oversight. It is not a supplement in any regulatory sense.
- The video's disclaimer about not stopping medications is valid, but it follows extended framing of those medications as ineffective, a combination that research on health communication shows reduces real-world adherence.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @drafroese actually say?
The core argument is this: dementia is a metabolic disease first and a brain disease second. The creator frames Alzheimer's as "type three diabetes," describing insulin resistance in the brain as the upstream driver of plaques, tangles, and cognitive decline. From there, the video pivots to peptides, specifically GLP-1 receptor agonists like semaglutide and a research compound called dihexa, as more promising interventions than current FDA-approved drugs. The creator is candid that dihexa evidence is animal-only so far, and explicitly tells viewers not to stop any medication. Credit where it is due: those disclaimers matter.
The claim that gets the most airtime is dihexa: it "crosses the blood-brain barrier," activates the HGF/c-Met pathway, and is "up to a million times more potent than BDNF" in animal models. The video cuts off before finishing the sentence about why there is hesitancy to test it in humans, which leaves viewers with a dangerously incomplete picture.
Does the science back this up?
The metabolic framing is genuinely supported by a growing body of research, but the dihexa claims need serious qualification. The "type 3 diabetes" hypothesis has real traction in neuroscience literature. De la Monte and Wands (2008, Journal of Alzheimer's Disease) first coined the term, and subsequent work has confirmed that brain insulin signaling is impaired in Alzheimer's patients independent of peripheral diabetes. That part of the video is largely accurate.
On dihexa: the potency claim traces back to McCoy et al. (2013, Journal of Pharmacology and Experimental Therapeutics), which did show dramatic effects on spatial learning in scopolamine-impaired rats. The HGF/c-Met pathway activation is real. However, the reason human trials have stalled is not just regulatory caution. There are concerns about HGF/c-Met signaling being a known oncogenic pathway. Amplifying it systemically in humans carries theoretical cancer risk that has never been resolved. The video never gets to that part.
What did they get wrong (or right)?
The creator gets the metabolic hypothesis mostly right. Insulin resistance, chronic inflammation, and mitochondrial dysfunction are all legitimate upstream contributors to neurodegeneration. The 2024 NEJM trial of lecanemab (van Dyck et al.) showed that even successful amyloid clearance produces modest clinical benefit, which does support the argument that plaques alone are not the whole story.
Where things get shaky is the framing around GLP-1 drugs. Saying "I've seen them do more good than harm" as a defense for dementia use is not evidence, it is anecdote. The ongoing EVOKE and REWIND trials are studying semaglutide and dulaglutide in cognitive outcomes respectively, but results are not yet conclusive. Presenting GLP-1 agents and dihexa as equivalent categories of "peptide therapy" is also misleading. One class has thousands of human trials behind it; the other has rodent data and a theoretical cancer concern. Lumping them together flattens a distinction that matters a lot to patients.
The disclaimer about not stopping medications is appreciated, but it follows several minutes of describing those same medications as things the creator "couldn't get behind." That framing will erode adherence regardless of the legal disclaimer that follows.
What should you actually know?
The metabolic model of dementia is a legitimate and active area of research, not fringe thinking. Addressing insulin resistance, inflammation, and cardiovascular risk factors in midlife is supported by the 2020 Lancet Commission on dementia prevention (Livingston et al.), which identified 12 modifiable risk factors accounting for roughly 40% of dementia cases. Exercise, sleep, blood pressure control, and treating diabetes are the interventions with the strongest evidence.
Dihexa is not available as an approved therapeutic. It is sold through unregulated peptide suppliers with no standardized dosing, no human safety data, and unresolved concerns about oncogenic risk given its mechanism. Anyone encountering it framed as a "supplement" should know it is nothing of the sort. GLP-1 receptor agonists are a different story, with active clinical trials in dementia, but those trials have not yet reported results that would justify use specifically for cognitive protection outside a study protocol.
- The "type 3 diabetes" framing is scientifically grounded but still a hypothesis, not a consensus diagnosis.
- Dihexa's potency claim comes from animal models only. No human safety or efficacy data exists.
- GLP-1 drugs are promising but not yet proven for dementia prevention or treatment.
- The HGF/c-Met pathway dihexa activates is also a known oncogenic pathway. That risk has never been studied in humans.
Bottom line
This video asks the right questions about dementia. The metabolic framing is not wrong, and the skepticism toward amyloid-only treatment models is shared by a lot of serious researchers. But the leap from "current drugs underperform" to "try this unregulated research peptide" skips over a canyon of missing safety data. Viewers deserve to hear both halves of that story.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Dr. Ashley Froese · TikTok creator
4.3K views on this video
Doctor Reveals TOP Peptides & Supplements To Help You Avoid Dementia #fyppppppppppppppppppppppp #healthcare #viraltiktok
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about the 2020 lancet commission (livingston et al.) identified 12 modifiable?
The 2020 Lancet Commission (Livingston et al.) identified 12 modifiable risk factors covering roughly 40% of dementia cases, with midlife cardiovascular and metabolic health among the strongest targets.
What does the video say about the 'type 3 diabetes' label for alzheimer's comes from de?
The 'type 3 diabetes' label for Alzheimer's comes from De la Monte and Wands (2008) and reflects genuine impairment of brain insulin signaling, but it remains a research hypothesis, not a clinical classification.
What does the video say about dihexa has shown dramatic pro-cognitive effects in rodent models (mccoy?
Dihexa has shown dramatic pro-cognitive effects in rodent models (McCoy et al., 2013) but has never been tested in humans, and its mechanism involves the HGF/c-Met pathway, which is also implicated in tumor growth.
What does the video say about glp-1 receptor agonists including semaglutide?
GLP-1 receptor agonists including semaglutide are in active human trials for cognitive outcomes, but no published trial to date supports prescribing them specifically to prevent or treat dementia.
What does the video say about lecanemab (van dyck et al., 2023, nejm) demonstrated?
Lecanemab (van Dyck et al., 2023, NEJM) demonstrated that clearing amyloid plaques slows decline by only 27% versus placebo, lending credibility to the argument that amyloid alone is not the full story.
What does the video say about dihexa?
Dihexa is sold through unregulated peptide suppliers with no standardized dosing, no human safety profile, and no FDA oversight. It is not a supplement in any regulatory sense.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Dr. Ashley Froese, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.